Cargando…

P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome

Detalles Bibliográficos
Autores principales:	Vassilakopoulos, Theodoros P., Liaskas, Athanasios, Rizzuto, Giuliana, Symeonidis, Argyrios, Palma, Marzia, Angelopoulou, Maria K., Giatra, Chara, Kondopidou, Flora, Dimou, Maria, Musseti, Alberto, Xagoraris, Ioanna, Siakantaris, Marina, Verigou, Evgenia, Panitsas, Fotios, Asimakopoulos, John, Arapaki, Maria, Chatzidimitriou, Chrysovalantou, Belia, Marina, Sachanas, Sotirios, Korkolopoulou, Penelope, Cabras, Antonello, Variamis, Eleni, Panayiotidis, Panayiotis, Bakiri, Maria, Karmiris, Themistoklis, Rassidakis, Georgios Z., Corradini, Paolo, Pangalis, Gerassimos, Viviani, Simonetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Relapsed/Refractory
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621510/ http://dx.doi.org/10.1097/01.HS9.0000891024.63916.91

Ejemplares similares

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
por: Michalka, Jozef, et al.
Publicado: (2022)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
por: Sureda-Balari, Anna, et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.
por: Kamel, Serageldin, et al.
Publicado: (2022)

P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience
por: Erenmalm, Axel, et al.
Publicado: (2022)

P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.
por: Mangasarova, Ya.K., et al.
Publicado: (2022)

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
por: Moatti, Hannah, et al.
Publicado: (2022)

T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
por: Moskowitz, Alison J., et al.
Publicado: (2022)

T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
por: Diefenbach, Catherine, et al.
Publicado: (2022)

P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
por: Viviani, Simonetta, et al.
Publicado: (2022)

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
por: Rusconi, Chiara, et al.
Publicado: (2022)

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data
por: Driessen, Julia, et al.
Publicado: (2022)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
por: Mei, Matthew, et al.
Publicado: (2022)

P113: Promising results with anti-PD-1 therapy in primary refractory Hodgkin lymphoma: a single-centre report
por: Zerbi, Caterina, et al.
Publicado: (2022)

Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2022)

Principles of heat treament
por: Grossmann, M A
Publicado: (1935)

Stimulants in the Treament of Disease
Publicado: (1870)

Immunohistochemical Analysis of IL-6, IL-8/CXCR2 Axis, (Tyr)p-STAT-3, and SOCS-3 in Lymph Nodes from Patients with Chronic Lymphocytic Leukemia: Correlation between Microvascular Characteristics and Prognostic Significance
por: Levidou, Georgia, et al.
Publicado: (2014)

Treament of Hæmoptysis by Ergot of Rye
por: Dobell, Horace
Publicado: (1869)

Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma
por: Chatzidimitriou, Chrysovalantou, et al.
Publicado: (2021)

Group protests treament of hadrons at CERN
Publicado: (2008)

New Insights into Monoclonal B-Cell Lymphocytosis
por: Kalpadakis, Christina, et al.
Publicado: (2014)

OSTEOTOMY AT THE BASE OF FEMORAL NECK AND OSTEOPLASTY FOR THE TREAMENT OF SCFE
por: GARCIA, LARISSA MARTINS, et al.
Publicado: (2022)

P1121: POSITRON EMISSION TOMOGRAPHY FOR FINAL RESPONSE ASSESSMENT TO RITUXIMAB-DOSE ADJUSTED EPOCH IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: WHO IS WORTHY TO BE IRRADIATED?
por: Vassilakopoulos, Theodoros, et al.
Publicado: (2023)

P1230: PET/CT IMAGING FOR RESPONSE ASSESSMENT AND TREATMENT GUIDANCE AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH(R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL):THE GREEK EXPERIENCE ON 107 PATIENTS
por: Vassilakopoulos, T., et al.
Publicado: (2022)

Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome
por: Lakiotaki, Eleftheria, et al.
Publicado: (2016)

PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2023)

Multimodal imaging-based diagnostic approach for MRI-negative posterior cortex epilepsy
por: Mo, Jiajie, et al.
Publicado: (2023)

Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia
por: Sarris, Katerina, et al.
Publicado: (2013)

The Abnormal CD4+T Lymphocyte Subset Distribution and Vbeta Repertoire in New-onset Rheumatoid Arthritis Can Be Modulated by Methotrexate Treament
por: Monserrat, Jorge, et al.
Publicado: (2019)

Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2019)

Neuroprotective Effects of Pre-Treament with l-Carnitine and Acetyl-l-Carnitine on Ischemic Injury In Vivo and In Vitro
por: Zhang, Rui, et al.
Publicado: (2012)

Integrating Network Pharmacology and Metabolomics to Elucidate the Mechanism of Action of Huang Qin Decoction for Treament of Diabetic Liver Injury
por: Xu, Xiaomin, et al.
Publicado: (2022)

Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia
por: Kyrtsonis, Marie-Christine, et al.
Publicado: (2014)

From restrictive to more liberal: variations in moratlity among patients in opioid maintenance treament over a 12-year period
por: Bukten, Anne, et al.
Publicado: (2019)

Managing Substance Use Disorder through a Walking/Running Training Program
por: Dai, Chia-Liang, et al.
Publicado: (2020)

New Insights into Malignant B-Cell Disorders
por: Kyrtsonis, Marie-Christine, et al.
Publicado: (2015)

PB2171: THE NOVEL CSN5/JAB1 INHIBITOR CSN5I-3 SUPPRESSES CELL GROWTH AND UPREGULATES GENE EXPRESSION OF TYPE-I INTERFERONS (IFN) IN ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
por: Xagoraris, I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_841sho7q767era4hilj1u5qbs1